# S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

> **NCT01925131** · PHASE1 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 50 (actual)

## Conditions studied

- Acute Leukemias of Ambiguous Lineage
- B-cell Adult Acute Lymphoblastic Leukemia
- Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Burkitt Lymphoma

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **BIOLOGICAL:** inotuzumab ozogamicin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01925131
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-13
- **Primary completion:** 2022-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925131, "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01925131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*